Markets KROS

Keros Therapeutics Authorizes Additional $5 Mln Share Repurchase Program

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Monday announced that its board of directors has approved an additional $5 million share repurchase program.

The approval follows the company's receipt of a $20 million development milestone payment under its license agreement with Takeda Pharmaceuticals U.S.A., Inc. (TAK)

The company said that the payment was triggered by the dosing of the first patient in the ELRiSE MF clinical trial of elritercept.

Keros Therapeutics closed trading 2.62% lesser at $10.03 on the Nasdaq. In after-hours trading, the stock traded 0.30% higher at $10.03.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Stocks Mentioned

Latest Articles

Data is currently not available